Magnhild Sandberg-Wollheim

Summary

Affiliation: Wallenberg Neuroscience Center
Country: Sweden

Publications

  1. ncbi request reprint Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up
    Petra Nilsson
    Department of Neurology, University Hospital, 22185 Lund, Sweden
    J Neurol 252:396-402. 2005
  2. ncbi request reprint Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study
    M Sandberg-Wollheim
    Department of Neurology, University Hospital, 221 85 Lund, Sweden
    J Neurol 252:8-13. 2005
  3. ncbi request reprint Interferon-beta1a treatment for multiple sclerosis
    Magnhild Sandberg-Wollheim
    Department of Neurology, University Hospital, Lund, Sweden
    Expert Rev Neurother 5:25-34. 2005
  4. ncbi request reprint Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis
    M Sandberg-Wollheim
    Department of Neurology, University Hospital, Lund, Sweden
    Neurology 65:802-6. 2005
  5. doi request reprint The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings
    Magnhild Sandberg-Wollheim
    Department of Neurology, University Hospital, University of Lund, Sweden
    Mult Scler 17:431-40. 2011
  6. doi request reprint Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy
    Magnhild Sandberg-Wollheim
    Department of Neurology, University Hospital, Lund, Sweden
    Mult Scler 17:423-30. 2011
  7. ncbi request reprint Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA
    Arch Neurol 62:785-92. 2005
  8. ncbi request reprint Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients
    Hanne F Harbo
    Institute of Immunology, Rikshospitalet University Hospital, 0027 Oslo, Norway
    J Neuroimmunol 143:101-6. 2003
  9. ncbi request reprint Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"
    Chris H Polman
    VU Medical Center Amsterdam, Free University, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Neurol 58:840-6. 2005

Detail Information

Publications9

  1. ncbi request reprint Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up
    Petra Nilsson
    Department of Neurology, University Hospital, 22185 Lund, Sweden
    J Neurol 252:396-402. 2005
    ..We reported previously on our cohort of 86 patients with acute monosymptomatic unilateral ON of whom 33 had progressed to MS after up to 18 years. Three patients had died. The present study extends the observation period to 31 years...
  2. ncbi request reprint Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study
    M Sandberg-Wollheim
    Department of Neurology, University Hospital, 221 85 Lund, Sweden
    J Neurol 252:8-13. 2005
    ....
  3. ncbi request reprint Interferon-beta1a treatment for multiple sclerosis
    Magnhild Sandberg-Wollheim
    Department of Neurology, University Hospital, Lund, Sweden
    Expert Rev Neurother 5:25-34. 2005
    ..These include uncertain benefit on conversion to secondary-progressive multiple sclerosis, the relevance of neutralizing antibodies and the controversial effect on multiple sclerosis-related brain atrophy...
  4. ncbi request reprint Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis
    M Sandberg-Wollheim
    Department of Neurology, University Hospital, Lund, Sweden
    Neurology 65:802-6. 2005
    ..Although patients with multiple sclerosis (MS) are advised to stop interferon (IFN) beta-1a therapy before becoming pregnant, some patients become pregnant while on treatment...
  5. doi request reprint The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings
    Magnhild Sandberg-Wollheim
    Department of Neurology, University Hospital, University of Lund, Sweden
    Mult Scler 17:431-40. 2011
    ..Risks that are potentially associated with long-term therapies should be assessed...
  6. doi request reprint Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy
    Magnhild Sandberg-Wollheim
    Department of Neurology, University Hospital, Lund, Sweden
    Mult Scler 17:423-30. 2011
    ..Women with multiple sclerosis (MS) are advised to discontinue interferon-beta therapy before trying to conceive. Unplanned pregnancies occur and risks related to exposure remain unclear...
  7. ncbi request reprint Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA
    Arch Neurol 62:785-92. 2005
    ....
  8. ncbi request reprint Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients
    Hanne F Harbo
    Institute of Immunology, Rikshospitalet University Hospital, 0027 Oslo, Norway
    J Neuroimmunol 143:101-6. 2003
    ..Usable data were achieved from the same 3331 markers in both screens. Nine markers from eight genomic regions (1p33, 3q13, 6p21, 6q14, 7p22, 9p21, 9q21 and Xq22) were identified as potentially associated with MS in both screens...
  9. ncbi request reprint Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"
    Chris H Polman
    VU Medical Center Amsterdam, Free University, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Neurol 58:840-6. 2005
    ..The 2005 Revisions to the McDonald Diagnostic Criteria for MS should simplify and speed diagnosis, whereas maintaining adequate sensitivity and specificity...